Yingsheng Biology

Shandong Yingsheng Biotechnology Co., Ltd., operating as Yingsheng Biology, is a high-tech enterprise established in 2009 that integrates research and development, production, sales, and third-party medical testing services. The company was founded by Mr. Feng, who currently serves as the Chairman and Managing Director. He and his team are recognized for their deep understanding of the Chinese clinical mass spectrometry market.

Yingsheng Biology focuses on the in vitro diagnostics (IVD) market, particularly in the area of clinical mass spectrometry, which is considered a significant growth area in the diagnostics industry. The firm provides one-stop solutions for clinical mass spectrometry laboratories. Its business model encompasses the entire value chain from manufacturing analytical instruments and automated pre-processing platforms to producing a wide array of IVD reagents and offering medical testing services through its own inspection institutions in Hebei and Shandong. The company generates revenue through the sale of these products and services to hospitals and clinical laboratories.

The company's product portfolio is extensive, built around metabolomics and genomics to address birth defect screening, disease prevention, and human health services. Key products include the YS Ext 9900 and YS Ext 9050MD high-performance liquid chromatography-mass spectrometry (LC-MS) systems and the YS Ext 8600MD inductively coupled plasma mass spectrometer (ICP-MS). Yingsheng Biology also produces a range of diagnostic kits, such as those for neonatal genetic and metabolic disease screening, full-spectrum vitamin testing, and genetic testing for hereditary and drug-induced deafness. In 2020, the company developed a COVID-19 nucleic acid detection kit and received approval for its full-spectrum 14-vitamin testing kit.

Yingsheng Biology has achieved several key milestones, including securing multiple rounds of financing from prominent investors. The company completed a Series B financing round in November 2020 and a Series C round in March 2022, attracting capital from firms like CICC Capital, Far East Horizon, and Hillhouse. These funding rounds have been aimed at accelerating market expansion, consolidating the industrial chain, and maintaining a leading edge in product development.

Keywords: clinical mass spectrometry, in vitro diagnostics, IVD, medical diagnostic equipment, genetic testing, neonatal screening, birth defect screening, metabolomics, genomics, diagnostic reagents, liquid chromatography-mass spectrometry, LC-MS, inductively coupled plasma mass spectrometer, ICP-MS, vitamin testing, disease prevention, third-party medical testing, molecular diagnostics, hereditary deafness testing, Shandong, China Taiping Insurance, CICC Jia Cheng, Far East Horizon, Jingming Innovation Capital, CDBI Partners